Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-12-10

AUTHORS

Charles-Edouard Luyt, Marc Clavel, Kalpalatha Guntupalli, Jay Johannigman, John I Kennedy, Christopher Wood, Kevin Corkery, Dennis Gribben, Jean Chastre

ABSTRACT

IntroductionAminoglycosides aerosolization might achieve better diffusion into the alveolar compartment than intravenous use. The objective of this multicenter study was to evaluate aerosol-delivered amikacin penetration into the alveolar epithelial lining fluid (ELF) using a new vibrating mesh nebulizer (Pulmonary Drug Delivery System (PDDS), Nektar Therapeutics), which delivers high doses to the lungs.MethodsNebulized amikacin (400 mg bid) was delivered to the lungs of 28 mechanically ventilated patients with Gram-negative VAP for 7-14 days, adjunctive to intravenous therapy. On treatment day 3, 30 minutes after completing aerosol delivery, all the patients underwent bronchoalveolar lavage in the infection-involved area and the ELF amikacin concentration was determined. The same day, urine and serum amikacin concentrations were determined at different time points.ResultsMedian (range) ELF amikacin and maximum serum amikacin concentrations were 976.1 (135.7-16127.6) and 0.9 (0.62-1.73) μg/mL, respectively. The median total amount of amikacin excreted in urine during the first and second 12-hour collection on day 3 were 19 (12.21-28) and 21.2 (14.1-29.98) μg, respectively. During the study period, daily through amikacin measurements were below the level of nephrotoxicity. Sixty-four unexpected adverse events were reported, among which 2 were deemed possibly due to nebulized amikacin: one episode of worsening renal failure, and one episode of bronchospasm.ConclusionsPDDS delivery of aerosolized amikacin achieved very high aminoglycoside concentrations in ELF from radiography-controlled infection-involved zones, while maintaining safe serum amikacin concentrations. The ELF concentrations always exceeded the amikacin minimum inhibitory concentrations for Gram-negative microorganisms usually responsible for these pneumonias. The clinical impact of amikacin delivery with this system remains to be determined.Trial RegistrationClinicalTrials.gov Identifier: NCT01021436. More... »

PAGES

r200

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/cc8206

DOI

http://dx.doi.org/10.1186/cc8206

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010862289

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20003269


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aerosols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amikacin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross Infection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Negative Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intubation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiration, Artificial", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de R\u00e9animation M\u00e9dicale, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris-Pierre-et-Marie-Curie, 47 boulevard de l'H\u00f4pital, 75651, Cedex 13, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "Service de R\u00e9animation M\u00e9dicale, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris-Pierre-et-Marie-Curie, 47 boulevard de l'H\u00f4pital, 75651, Cedex 13, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luyt", 
        "givenName": "Charles-Edouard", 
        "id": "sg:person.01310337776.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310337776.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de R\u00e9animation M\u00e9dicale, Centre Hospitalier Dupuytren, 2 avenue Martin Luther King, 87000, Limoges, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service de R\u00e9animation M\u00e9dicale, Centre Hospitalier Dupuytren, 2 avenue Martin Luther King, 87000, Limoges, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clavel", 
        "givenName": "Marc", 
        "id": "sg:person.0576433535.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576433535.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Critical Care, Baylor College of Medicine, One Baylor Plazza, TX 77030, Houston, USA", 
          "id": "http://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Critical Care, Baylor College of Medicine, One Baylor Plazza, TX 77030, Houston, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guntupalli", 
        "givenName": "Kalpalatha", 
        "id": "sg:person.01052233261.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052233261.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Division of Trauma/Critical Care, University of Cincinnati, 2600 Clifton Avenue, OH 45221, Cincinnati, USA", 
          "id": "http://www.grid.ac/institutes/grid.24827.3b", 
          "name": [
            "Department of Surgery, Division of Trauma/Critical Care, University of Cincinnati, 2600 Clifton Avenue, OH 45221, Cincinnati, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johannigman", 
        "givenName": "Jay", 
        "id": "sg:person.0601034534.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601034534.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care Medicine, University of Alabama, 1802 6th Avenue South, AL 35249, Birmingham, USA", 
          "id": "http://www.grid.ac/institutes/grid.411015.0", 
          "name": [
            "Division of Pulmonary and Critical Care Medicine, University of Alabama, 1802 6th Avenue South, AL 35249, Birmingham, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kennedy", 
        "givenName": "John I", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Critical Care Department, University of Tennessee Health Science Center, 920 Madison Avenue, TN 38163, Memphis, USA", 
          "id": "http://www.grid.ac/institutes/grid.267301.1", 
          "name": [
            "Critical Care Department, University of Tennessee Health Science Center, 920 Madison Avenue, TN 38163, Memphis, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher", 
        "id": "sg:person.01104632232.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104632232.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceutical Corp, 150 Industrial Road, CA 94070, San Carlos, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Novartis Pharmaceutical Corp, 150 Industrial Road, CA 94070, San Carlos, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corkery", 
        "givenName": "Kevin", 
        "id": "sg:person.0752144541.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144541.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Talima Therapeutics, 75 Shoreway Road, CA 94070, San Carlos, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Talima Therapeutics, 75 Shoreway Road, CA 94070, San Carlos, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gribben", 
        "givenName": "Dennis", 
        "id": "sg:person.01031433002.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031433002.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de R\u00e9animation M\u00e9dicale, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris-Pierre-et-Marie-Curie, 47 boulevard de l'H\u00f4pital, 75651, Cedex 13, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "Service de R\u00e9animation M\u00e9dicale, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris-Pierre-et-Marie-Curie, 47 boulevard de l'H\u00f4pital, 75651, Cedex 13, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chastre", 
        "givenName": "Jean", 
        "id": "sg:person.0714077601.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00134-007-0688-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040595249", 
          "https://doi.org/10.1007/s00134-007-0688-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-007-0562-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037016801", 
          "https://doi.org/10.1007/s00134-007-0562-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-008-1126-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000713512", 
          "https://doi.org/10.1007/s00134-008-1126-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-007-0935-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022084897", 
          "https://doi.org/10.1007/s00134-007-0935-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-12-10", 
    "datePublishedReg": "2009-12-10", 
    "description": "IntroductionAminoglycosides aerosolization might achieve better diffusion into the alveolar compartment than intravenous use. The objective of this multicenter study was to evaluate aerosol-delivered amikacin penetration into the alveolar epithelial lining fluid (ELF) using a new vibrating mesh nebulizer (Pulmonary Drug Delivery System (PDDS), Nektar Therapeutics), which delivers high doses to the lungs.MethodsNebulized amikacin (400 mg bid) was delivered to the lungs of 28 mechanically ventilated patients with Gram-negative VAP for 7-14 days, adjunctive to intravenous therapy. On treatment day 3, 30 minutes after completing aerosol delivery, all the patients underwent bronchoalveolar lavage in the infection-involved area and the ELF amikacin concentration was determined. The same day, urine and serum amikacin concentrations were determined at different time points.ResultsMedian (range) ELF amikacin and maximum serum amikacin concentrations were 976.1 (135.7-16127.6) and 0.9 (0.62-1.73) \u03bcg/mL, respectively. The median total amount of amikacin excreted in urine during the first and second 12-hour collection on day 3 were 19 (12.21-28) and 21.2 (14.1-29.98) \u03bcg, respectively. During the study period, daily through amikacin measurements were below the level of nephrotoxicity. Sixty-four unexpected adverse events were reported, among which 2 were deemed possibly due to nebulized amikacin: one episode of worsening renal failure, and one episode of bronchospasm.ConclusionsPDDS delivery of aerosolized amikacin achieved very high aminoglycoside concentrations in ELF from radiography-controlled infection-involved zones, while maintaining safe serum amikacin concentrations. The ELF concentrations always exceeded the amikacin minimum inhibitory concentrations for Gram-negative microorganisms usually responsible for these pneumonias. The clinical impact of amikacin delivery with this system remains to be determined.Trial RegistrationClinicalTrials.gov Identifier: NCT01021436.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/cc8206", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1117766", 
        "issn": [
          "1364-8535", 
          "1466-609X"
        ], 
        "name": "Critical Care", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "serum amikacin concentrations", 
      "epithelial lining fluid", 
      "amikacin concentrations", 
      "day 3", 
      "amikacin minimum inhibitory concentrations", 
      "alveolar epithelial lining fluid", 
      "level of nephrotoxicity", 
      "episodes of bronchospasm", 
      "high aminoglycoside concentrations", 
      "treatment day 3", 
      "unexpected adverse events", 
      "median total amount", 
      "nosocomial pneumonia", 
      "different time points", 
      "renal failure", 
      "intravenous therapy", 
      "adverse events", 
      "ELF concentrations", 
      "bronchoalveolar lavage", 
      "multicenter study", 
      "minimum inhibitory concentration", 
      "intravenous use", 
      "aerosol delivery", 
      "clinical impact", 
      "lining fluid", 
      "aminoglycoside concentrations", 
      "alveolar compartment", 
      "high doses", 
      "amikacin", 
      "mesh nebulizer", 
      "lung delivery", 
      "patients", 
      "amikacin delivery", 
      "study period", 
      "time points", 
      "same day", 
      "inhibitory concentration", 
      "Gram-negative microorganisms", 
      "pneumonia", 
      "lung", 
      "urine", 
      "delivery", 
      "episodes", 
      "days", 
      "bronchospasm", 
      "lavage", 
      "nephrotoxicity", 
      "therapy", 
      "pharmacokinetics", 
      "doses", 
      "VAP", 
      "aerosolization", 
      "concentration", 
      "minutes", 
      "nebulizer", 
      "failure", 
      "total amount", 
      "compartments", 
      "period", 
      "levels", 
      "study", 
      "events", 
      "fluid", 
      "objective", 
      "use", 
      "better diffusion", 
      "impact", 
      "area", 
      "penetration", 
      "microorganisms", 
      "collection", 
      "identifiers", 
      "amount", 
      "point", 
      "measurements", 
      "system", 
      "zone", 
      "diffusion"
    ], 
    "name": "Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia", 
    "pagination": "r200", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010862289"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/cc8206"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20003269"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/cc8206", 
      "https://app.dimensions.ai/details/publication/pub.1010862289"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_496.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/cc8206"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/cc8206'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/cc8206'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/cc8206'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/cc8206'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      21 PREDICATES      116 URIs      104 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/cc8206 schema:about N0ae003d67da34456b512855546cff450
2 N28ca1c76778145dc8667beb2b79aa414
3 N40b5d1662c37404ba5611b87ffc20ac2
4 N57b16c7200db48c0b8ad6caca60ad521
5 N5afbac8a052d4b9ca4fc108e29f00619
6 N864ad41f97aa43dfb1e5f2b073e1359f
7 Nacb0a8883d674087afe3561f2e1f6883
8 Ne2ae8f17c8bf40d28e636658d06fd3c9
9 Nea88c6b0254546439c34db9c3c4d4df5
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author Nfcc174d7eda840e6a670d123aa4df6f3
13 schema:citation sg:pub.10.1007/s00134-007-0562-x
14 sg:pub.10.1007/s00134-007-0688-x
15 sg:pub.10.1007/s00134-007-0935-1
16 sg:pub.10.1007/s00134-008-1126-4
17 schema:datePublished 2009-12-10
18 schema:datePublishedReg 2009-12-10
19 schema:description IntroductionAminoglycosides aerosolization might achieve better diffusion into the alveolar compartment than intravenous use. The objective of this multicenter study was to evaluate aerosol-delivered amikacin penetration into the alveolar epithelial lining fluid (ELF) using a new vibrating mesh nebulizer (Pulmonary Drug Delivery System (PDDS), Nektar Therapeutics), which delivers high doses to the lungs.MethodsNebulized amikacin (400 mg bid) was delivered to the lungs of 28 mechanically ventilated patients with Gram-negative VAP for 7-14 days, adjunctive to intravenous therapy. On treatment day 3, 30 minutes after completing aerosol delivery, all the patients underwent bronchoalveolar lavage in the infection-involved area and the ELF amikacin concentration was determined. The same day, urine and serum amikacin concentrations were determined at different time points.ResultsMedian (range) ELF amikacin and maximum serum amikacin concentrations were 976.1 (135.7-16127.6) and 0.9 (0.62-1.73) μg/mL, respectively. The median total amount of amikacin excreted in urine during the first and second 12-hour collection on day 3 were 19 (12.21-28) and 21.2 (14.1-29.98) μg, respectively. During the study period, daily through amikacin measurements were below the level of nephrotoxicity. Sixty-four unexpected adverse events were reported, among which 2 were deemed possibly due to nebulized amikacin: one episode of worsening renal failure, and one episode of bronchospasm.ConclusionsPDDS delivery of aerosolized amikacin achieved very high aminoglycoside concentrations in ELF from radiography-controlled infection-involved zones, while maintaining safe serum amikacin concentrations. The ELF concentrations always exceeded the amikacin minimum inhibitory concentrations for Gram-negative microorganisms usually responsible for these pneumonias. The clinical impact of amikacin delivery with this system remains to be determined.Trial RegistrationClinicalTrials.gov Identifier: NCT01021436.
20 schema:genre article
21 schema:isAccessibleForFree true
22 schema:isPartOf N033b1f7b53d245b28ea28301aa5b54af
23 Nabe348890dbf43d980d472d43197134a
24 sg:journal.1117766
25 schema:keywords ELF concentrations
26 Gram-negative microorganisms
27 VAP
28 adverse events
29 aerosol delivery
30 aerosolization
31 alveolar compartment
32 alveolar epithelial lining fluid
33 amikacin
34 amikacin concentrations
35 amikacin delivery
36 amikacin minimum inhibitory concentrations
37 aminoglycoside concentrations
38 amount
39 area
40 better diffusion
41 bronchoalveolar lavage
42 bronchospasm
43 clinical impact
44 collection
45 compartments
46 concentration
47 day 3
48 days
49 delivery
50 different time points
51 diffusion
52 doses
53 episodes
54 episodes of bronchospasm
55 epithelial lining fluid
56 events
57 failure
58 fluid
59 high aminoglycoside concentrations
60 high doses
61 identifiers
62 impact
63 inhibitory concentration
64 intravenous therapy
65 intravenous use
66 lavage
67 level of nephrotoxicity
68 levels
69 lining fluid
70 lung
71 lung delivery
72 measurements
73 median total amount
74 mesh nebulizer
75 microorganisms
76 minimum inhibitory concentration
77 minutes
78 multicenter study
79 nebulizer
80 nephrotoxicity
81 nosocomial pneumonia
82 objective
83 patients
84 penetration
85 period
86 pharmacokinetics
87 pneumonia
88 point
89 renal failure
90 same day
91 serum amikacin concentrations
92 study
93 study period
94 system
95 therapy
96 time points
97 total amount
98 treatment day 3
99 unexpected adverse events
100 urine
101 use
102 zone
103 schema:name Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia
104 schema:pagination r200
105 schema:productId N22c8a55f7a1949658e519af25a63b9e4
106 N8ac64a21b8374dfea4c687fb3b05f58c
107 Ne6a83cec991540e1ae7290b7e21854b8
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010862289
109 https://doi.org/10.1186/cc8206
110 schema:sdDatePublished 2022-09-02T15:54
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N97ab2afb2c314784b46f7f055c3ddafc
113 schema:url https://doi.org/10.1186/cc8206
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N033b1f7b53d245b28ea28301aa5b54af schema:volumeNumber 13
118 rdf:type schema:PublicationVolume
119 N0ae003d67da34456b512855546cff450 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Aerosols
121 rdf:type schema:DefinedTerm
122 N22c8a55f7a1949658e519af25a63b9e4 schema:name doi
123 schema:value 10.1186/cc8206
124 rdf:type schema:PropertyValue
125 N246b44cb3d1c4512bd3f2b981b90fe7f rdf:first sg:person.0576433535.50
126 rdf:rest N8767818f1da94edabf1390f5d658779b
127 N28ca1c76778145dc8667beb2b79aa414 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Intubation
129 rdf:type schema:DefinedTerm
130 N3cb28d2216fd42599da2fdfdcee90642 rdf:first sg:person.0601034534.10
131 rdf:rest Nd346e3f647824b968987c99a7cf52961
132 N40b5d1662c37404ba5611b87ffc20ac2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Respiration, Artificial
134 rdf:type schema:DefinedTerm
135 N57b16c7200db48c0b8ad6caca60ad521 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Anti-Bacterial Agents
137 rdf:type schema:DefinedTerm
138 N5afbac8a052d4b9ca4fc108e29f00619 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 N864ad41f97aa43dfb1e5f2b073e1359f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Gram-Negative Bacterial Infections
143 rdf:type schema:DefinedTerm
144 N8767818f1da94edabf1390f5d658779b rdf:first sg:person.01052233261.87
145 rdf:rest N3cb28d2216fd42599da2fdfdcee90642
146 N880d9a076cea4b6d9a608e344f7f3429 rdf:first sg:person.0714077601.27
147 rdf:rest rdf:nil
148 N8ac64a21b8374dfea4c687fb3b05f58c schema:name dimensions_id
149 schema:value pub.1010862289
150 rdf:type schema:PropertyValue
151 N97ab2afb2c314784b46f7f055c3ddafc schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 N9c859637b9f84c0bb506019ca6395d1e schema:affiliation grid-institutes:grid.411015.0
154 schema:familyName Kennedy
155 schema:givenName John I
156 rdf:type schema:Person
157 Nabe348890dbf43d980d472d43197134a schema:issueNumber 6
158 rdf:type schema:PublicationIssue
159 Nacb0a8883d674087afe3561f2e1f6883 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Cross Infection
161 rdf:type schema:DefinedTerm
162 Nc02bcc54f2924f32854b2c19a0561990 rdf:first sg:person.01104632232.16
163 rdf:rest Nf4e162a90b0e4bae8148714742f8a44a
164 Nd346e3f647824b968987c99a7cf52961 rdf:first N9c859637b9f84c0bb506019ca6395d1e
165 rdf:rest Nc02bcc54f2924f32854b2c19a0561990
166 Nd8f9ecbabc334d4e8c7032d2bdb3f568 rdf:first sg:person.01031433002.96
167 rdf:rest N880d9a076cea4b6d9a608e344f7f3429
168 Ne2ae8f17c8bf40d28e636658d06fd3c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Lung
170 rdf:type schema:DefinedTerm
171 Ne6a83cec991540e1ae7290b7e21854b8 schema:name pubmed_id
172 schema:value 20003269
173 rdf:type schema:PropertyValue
174 Nea88c6b0254546439c34db9c3c4d4df5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Amikacin
176 rdf:type schema:DefinedTerm
177 Nf4e162a90b0e4bae8148714742f8a44a rdf:first sg:person.0752144541.89
178 rdf:rest Nd8f9ecbabc334d4e8c7032d2bdb3f568
179 Nfcc174d7eda840e6a670d123aa4df6f3 rdf:first sg:person.01310337776.72
180 rdf:rest N246b44cb3d1c4512bd3f2b981b90fe7f
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
185 schema:name Clinical Sciences
186 rdf:type schema:DefinedTerm
187 sg:journal.1117766 schema:issn 1364-8535
188 1466-609X
189 schema:name Critical Care
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01031433002.96 schema:affiliation grid-institutes:None
193 schema:familyName Gribben
194 schema:givenName Dennis
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031433002.96
196 rdf:type schema:Person
197 sg:person.01052233261.87 schema:affiliation grid-institutes:grid.39382.33
198 schema:familyName Guntupalli
199 schema:givenName Kalpalatha
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052233261.87
201 rdf:type schema:Person
202 sg:person.01104632232.16 schema:affiliation grid-institutes:grid.267301.1
203 schema:familyName Wood
204 schema:givenName Christopher
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104632232.16
206 rdf:type schema:Person
207 sg:person.01310337776.72 schema:affiliation grid-institutes:grid.411439.a
208 schema:familyName Luyt
209 schema:givenName Charles-Edouard
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310337776.72
211 rdf:type schema:Person
212 sg:person.0576433535.50 schema:affiliation grid-institutes:None
213 schema:familyName Clavel
214 schema:givenName Marc
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576433535.50
216 rdf:type schema:Person
217 sg:person.0601034534.10 schema:affiliation grid-institutes:grid.24827.3b
218 schema:familyName Johannigman
219 schema:givenName Jay
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601034534.10
221 rdf:type schema:Person
222 sg:person.0714077601.27 schema:affiliation grid-institutes:grid.411439.a
223 schema:familyName Chastre
224 schema:givenName Jean
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27
226 rdf:type schema:Person
227 sg:person.0752144541.89 schema:affiliation grid-institutes:None
228 schema:familyName Corkery
229 schema:givenName Kevin
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144541.89
231 rdf:type schema:Person
232 sg:pub.10.1007/s00134-007-0562-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037016801
233 https://doi.org/10.1007/s00134-007-0562-x
234 rdf:type schema:CreativeWork
235 sg:pub.10.1007/s00134-007-0688-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040595249
236 https://doi.org/10.1007/s00134-007-0688-x
237 rdf:type schema:CreativeWork
238 sg:pub.10.1007/s00134-007-0935-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022084897
239 https://doi.org/10.1007/s00134-007-0935-1
240 rdf:type schema:CreativeWork
241 sg:pub.10.1007/s00134-008-1126-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000713512
242 https://doi.org/10.1007/s00134-008-1126-4
243 rdf:type schema:CreativeWork
244 grid-institutes:None schema:alternateName Novartis Pharmaceutical Corp, 150 Industrial Road, CA 94070, San Carlos, USA
245 Service de Réanimation Médicale, Centre Hospitalier Dupuytren, 2 avenue Martin Luther King, 87000, Limoges, France
246 Talima Therapeutics, 75 Shoreway Road, CA 94070, San Carlos, USA
247 schema:name Novartis Pharmaceutical Corp, 150 Industrial Road, CA 94070, San Carlos, USA
248 Service de Réanimation Médicale, Centre Hospitalier Dupuytren, 2 avenue Martin Luther King, 87000, Limoges, France
249 Talima Therapeutics, 75 Shoreway Road, CA 94070, San Carlos, USA
250 rdf:type schema:Organization
251 grid-institutes:grid.24827.3b schema:alternateName Department of Surgery, Division of Trauma/Critical Care, University of Cincinnati, 2600 Clifton Avenue, OH 45221, Cincinnati, USA
252 schema:name Department of Surgery, Division of Trauma/Critical Care, University of Cincinnati, 2600 Clifton Avenue, OH 45221, Cincinnati, USA
253 rdf:type schema:Organization
254 grid-institutes:grid.267301.1 schema:alternateName Critical Care Department, University of Tennessee Health Science Center, 920 Madison Avenue, TN 38163, Memphis, USA
255 schema:name Critical Care Department, University of Tennessee Health Science Center, 920 Madison Avenue, TN 38163, Memphis, USA
256 rdf:type schema:Organization
257 grid-institutes:grid.39382.33 schema:alternateName Critical Care, Baylor College of Medicine, One Baylor Plazza, TX 77030, Houston, USA
258 schema:name Critical Care, Baylor College of Medicine, One Baylor Plazza, TX 77030, Houston, USA
259 rdf:type schema:Organization
260 grid-institutes:grid.411015.0 schema:alternateName Division of Pulmonary and Critical Care Medicine, University of Alabama, 1802 6th Avenue South, AL 35249, Birmingham, USA
261 schema:name Division of Pulmonary and Critical Care Medicine, University of Alabama, 1802 6th Avenue South, AL 35249, Birmingham, USA
262 rdf:type schema:Organization
263 grid-institutes:grid.411439.a schema:alternateName Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Paris-Pierre-et-Marie-Curie, 47 boulevard de l'Hôpital, 75651, Cedex 13, Paris, France
264 schema:name Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Paris-Pierre-et-Marie-Curie, 47 boulevard de l'Hôpital, 75651, Cedex 13, Paris, France
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...